A REVIEW ON AGENTS FOR THE TREATMENT OF LEPROSY INFECTION
暂无分享,去创建一个
[1] P. Suffys,et al. Molecular epidemiology of leprosy: An update. , 2020, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[2] R. Siddiqui,et al. Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options. , 2020, Microbial pathogenesis.
[3] R. Dellavalle,et al. Leprosy: Treatment and Management of Complications. , 2020, Journal of the American Academy of Dermatology.
[4] Tamer M. Ibrahim,et al. New acrylamide-sulfisoxazole conjugates as dihydropteroate synthase inhibitors. , 2020, Bioorganic & medicinal chemistry.
[5] M. Jafer,et al. Epidemiological aspects of leprosy. , 2019, Disease-a-month : DM.
[6] Hayati Çelik,et al. Potent ribonucleotide reductase inhibitors: Thiazole‐containing thiosemicarbazone derivatives , 2019, Archiv der Pharmazie.
[7] B. Naafs,et al. Position statement: LEPROSY: Diagnosis, treatment and follow‐up , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.
[8] Widodo,et al. A new Mycobacterium leprae dihydropteroate synthase variant (V39I) from Papua, Indonesia , 2019, Heliyon.
[9] N. Oleinick,et al. Structure-guided design of anti-cancer ribonucleotide reductase inhibitors , 2019, Journal of enzyme inhibition and medicinal chemistry.
[10] F. Naaz,et al. Ribonucleotide reductase as a drug target against drug resistance Mycobacterium leprae: A molecular docking study. , 2018, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[11] J. R. de Sousa,et al. Nerve Growth Factor and Pathogenesis of Leprosy: Review and Update , 2018, Front. Immunol..
[12] L. Schuler‐Faccini,et al. Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition. , 2018, Acta tropica.
[13] A. Stone,et al. Mycobacterium leprae genomes from naturally infected nonhuman primates , 2018, PLoS neglected tropical diseases.
[14] M. Fischer. Leprosy – an overview of clinical features, diagnosis, and treatment , 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[15] A. Fernandes,et al. A ribonucleotide reductase inhibitor with deoxyribonucleoside‐reversible cytotoxicity , 2016, Molecular oncology.
[16] S. White,et al. Pterin-sulfa conjugates as dihydropteroate synthase inhibitors and antibacterial agents. , 2016, Bioorganic & medicinal chemistry letters.
[17] L. Abel,et al. Pauci- and Multibacillary Leprosy: Two Distinct, Genetically Neglected Diseases , 2016, PLoS neglected tropical diseases.
[18] S. Gupta. Histoid leprosy: review of the literature , 2015, International journal of dermatology.
[19] A. Aubry,et al. Update on the epidemiology, diagnosis, and treatment of leprosy. , 2015, Medecine et maladies infectieuses.
[20] E. Ignotti,et al. Inflammatory Mediators of Leprosy Reactional Episodes and Dental Infections: A Systematic Review , 2015, Mediators of inflammation.
[21] P. Steinmann,et al. Current knowledge on Mycobacterium leprae transmission: a systematic literature review. , 2015, Leprosy review.
[22] F. Baas,et al. M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator , 2015, Acta Neuropathologica.
[23] C. Franco-Paredes,et al. Leprosy in the 21st Century , 2015, Clinical Microbiology Reviews.
[24] J. Quaresma,et al. Relationship between growth factors and its implication in the pathogenesis of leprosy. , 2014, Microbial pathogenesis.
[25] E. Tortoli. Microbiological Features and Clinical Relevance of New Species of the Genus Mycobacterium , 2014, Clinical Microbiology Reviews.
[26] M. Ochoa,et al. Recognizing and managing the immunologic reactions in leprosy. , 2014, Journal of the American Academy of Dermatology.
[27] Sameh Eid,et al. Design, synthesis, antimicrobial evaluation and molecular docking studies of some new thiophene, pyrazole and pyridone derivatives bearing sulfisoxazole moiety. , 2014, European journal of medicinal chemistry.
[28] D. Falzon,et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies , 2014, BMJ Open.
[29] D. E. Antunes,et al. Identification of clinical, epidemiological and laboratory risk factors for leprosy reactions during and after multidrug therapy , 2013, Memorias do Instituto Oswaldo Cruz.
[30] J. Ocampo-Candiani,et al. Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment. , 2013, Actas dermo-sifiliograficas.
[31] D. Lockwood,et al. New findings in the pathogenesis of leprosy and implications for the management of leprosy , 2013, Current opinion in infectious diseases.
[32] Koichi Suzuki,et al. Clofazimine Modulates the Expression of Lipid Metabolism Proteins in Mycobacterium leprae-Infected Macrophages , 2012, PLoS neglected tropical diseases.
[33] Ruchi S. Gupta,et al. Revalidation of various clinical criteria for the classification of leprosy--a clinic-pathological study. , 2012, Leprosy review.
[34] R. Bhat,et al. Leprosy: An Overview of Pathophysiology , 2012, Interdisciplinary perspectives on infectious diseases.
[35] D. Scollard. Chemotherapy of leprosy has changed (almost) everything. , 2012, Leprosy review.
[36] J. Grosset,et al. The chemotherapy of leprosy: an interpretive history. , 2012, Leprosy review.
[37] D. Lockwood,et al. Nerve damage in leprosy: a continuing challenge to scientists, clinicians and service providers. , 2012, International health.
[38] J. Boivin,et al. Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta‐analysis , 2011, Tropical medicine & international health : TM & IH.
[39] D. Scollard,et al. Evaluation of Multi-Drug Therapy for Leprosy in the United States Using Daily Rifampin , 2011, Southern medical journal.
[40] M. Duthie,et al. Clinical, immunological, and genetic aspects in leprosy , 2011 .
[41] D. Lockwood,et al. Leprosy now: epidemiology, progress, challenges, and research gaps. , 2011, The Lancet. Infectious diseases.
[42] D. Scollard,et al. Hansen's disease (leprosy) complicated by secondary mycobacterial infection. , 2011, Journal of the American Academy of Dermatology.
[43] S. White,et al. Synthesis of bi-substrate state mimics of dihydropteroate synthase as potential inhibitors and molecular probes. , 2011, Bioorganic & medicinal chemistry.
[44] P. Prasad,et al. LEPROSY THERAPY, PAST AND PRESENT: CAN WE HOPE TO ELIMINATE IT? , 2010, Indian journal of dermatology.
[45] A. Agrawal. Clinical Management of Leprosy Reactions , 2010 .
[46] K. Hevener,et al. Structural studies of pterin-based inhibitors of dihydropteroate synthase. , 2009, Journal of medicinal chemistry.
[47] S. Worobec. Treatment of leprosy/Hansen's disease in the early 21st century , 2009, Dermatologic therapy.
[48] V. Gautam. Treatment of leprosy in India. , 2009, Journal of postgraduate medicine.
[49] Jun O. Liu,et al. Clofazimine Inhibits Human Kv1.3 Potassium Channel by Perturbing Calcium Oscillation in T Lymphocytes , 2008, PloS one.
[50] E. Wilder-Smith,et al. Nerve damage in leprosy and its management , 2008, Nature Clinical Practice Neurology.
[51] D. Lockwood,et al. Leprosy type 1 (reversal) reactions and their management. , 2008, Leprosy review.
[52] D. Scollard. The biology of nerve injury in leprosy. , 2008, Leprosy review.
[53] D. Lockwood,et al. Towards understanding the pathology of erythema nodosum leprosum. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[54] M. Robson,et al. Leprosy: Steps Along the Journey of Eradication , 2008, Public health reports.
[55] Maria Paola Costi,et al. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development , 2008, Proceedings of the National Academy of Sciences.
[56] S. Dogra,et al. The imperatives of leprosy treatment in the pre‐ and post‐global leprosy elimination era: Appraisal of changing the scenario to current status , 2008, The Journal of dermatological treatment.
[57] G. Rook,et al. Mycobacteria and allergies. , 2007, Immunobiology.
[58] Joseph I. Ambrus,et al. Dual action-based approaches to antibacterial agents. , 2007, Current medicinal chemistry.
[59] E. Tortoli. The new mycobacteria: an update. , 2006, FEMS immunology and medical microbiology.
[60] Diana J L Williams,et al. The Continuing Challenges of Leprosy , 2006, Clinical Microbiology Reviews.
[61] Rehana Tippoo,et al. MDT-MB therapy in paucibacillary leprosy: a clinicopathological assessment. , 2005, Indian journal of dermatology, venereology and leprology.
[62] J. Coppee,et al. On the Origin of Leprosy , 2005, Science.
[63] J. Srinivasan,et al. Leprosy and the peripheral nervous system: Basic and clinical aspects , 2004, Muscle & nerve.
[64] S. Moschella. An update on the diagnosis and treatment of leprosy. , 2004, Journal of the American Academy of Dermatology.
[65] S. Dogra,et al. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. , 2004, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.
[66] V. Katoch. Advances in the diagnosis and treatment of leprosy , 2002, Expert Reviews in Molecular Medicine.
[67] Nalin Rastogi,et al. The mycobacteria: an introduction to nomenclature and pathogenesis. , 2001, Revue scientifique et technique.
[68] Arkady Mustaev,et al. Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase , 2001, Cell.
[69] A. Rambukkana. Molecular basis for the peripheral nerve predilection of Mycobacterium leprae. , 2001, Current opinion in microbiology.
[70] W H Jopling,et al. Clinical aspects of leprosy. , 1982, Tubercle.
[71] R. Singh,et al. THE TREATMENT OF LEPROSY , 1948, Indian journal of dermatology.
[72] E. Muir. Recent advances in the treatment of leprosy. , 1948, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[73] R. Rao,et al. Chapter-31 Chemotherapy: Development and Evolution of WHO-MDT and Newer Treatment Regimens , 2017 .
[74] Arshdeep,et al. Minocycline in leprosy patients with recent onset clinical nerve function impairment , 2017, Dermatologic therapy.
[75] U. Khemani,et al. An alternative hepatosafe treatment in leprosy , 2016 .
[76] V. Pai. Role of clofazimine in management of reactions in leprosy: A brief overview , 2015 .
[77] M. Abreu,et al. Revista2Vol89ingles2_Layout 1 , 2014 .
[78] Suman Jain,et al. Newer Management Options in Leprosy , 2013, Indian journal of dermatology.
[79] O. Parkash. Classification of leprosy into multibacillary and paucibacillary groups: an analysis. , 2009, FEMS immunology and medical microbiology.
[80] R. Brosch,et al. Pathogenomics of mycobacteria. , 2009, Genome dynamics.
[81] M. Binitha,et al. A study of oxidative stress in paucibacillary and multibacillary leprosy. , 2008, Indian journal of dermatology, venereology and leprology.
[82] G. Pfyffer. Mycobacterium: General Characteristics, Laboratory Detection, and Staining Procedures* , 2006 .
[83] V. Somaraju. Drugs Used in Tuberculosis and Leprosy , 2003 .